ライフサイエンスコーパス: brachial

1 All infusions were intra-arterial (brachial).

2 EECP increased brachial (+51% versus +2%) and femoral (+30% versus +3%)

3 Brachial and aortic BP was lower in controls than in CKD

4 We measured baseline and post-DASH/SRD brachial and central blood pressure (via radial arterial

5 Flow-mediated dilation of the brachial and femoral arteries was performed with the use

6 in order to achieve functional repair after brachial and lumbosacral plexus avulsion injuries.

7 Both A (radial/brachial) and B (axillary/subclavian/innominate) variant

8 evaluate the role of large artery stiffness, brachial, and central blood pressure as predictors of in

9 d standard index of large artery stiffness), brachial, and central pressures (estimated via radial to

10 stiffness indices, in particular of carotid, brachial, and femoral stiffness, with cardiovascular dis

11 ed CD8 T cells arise in mesenteric, axillary/brachial, and mediastinal lymph nodes and spleen based o

12 Brachial-ankle pulse wave velocity (baPWV) was measured

13 Brachial-ankle PWV was significantly higher among Abeta-

14 , peripheral (femoral-ankle PWV), and mixed (brachial-ankle PWV) vascular beds.

15 asures, and the high sodium visit included a brachial arterial catheter for forearm vasodilator respo

16 Arterial pressure was measured by brachial arterial catheter, and cardiac output by acetyl

17 nal Doppler ultrasound was used to determine brachial arterial endothelial function.

18 sed local stiffness of carotid, femoral, and brachial arteries (by ultrasonography), carotid-femoral

19 inly rely on blood pressure (BP) measured at brachial arteries (cuff BP).

20 Brachial arteries of athletes were larger (Athletes 5.39

21 Elite power athletes have larger brachial arteries, and greater vasoreactivity (greater v

22 hemia induced by a surgical occlusion of the brachial artery (BAO) induces increased paw-guarding beh

23 lower in endothelial cells obtained from the brachial artery (P < 0.05), whereas EID did not differ.

24 and autologously transfused into the forearm brachial artery 5 and 42 days after blood donation.

25 y) for 45 min with catheters inserted in the brachial artery and both femoral veins.

26 ressed by a smaller percentage of FMD of the brachial artery and higher salivary levels of MMP-2/TIMP

27 Blood was sampled simultaneously from the brachial artery and internal jugular and femoral veins w

28 essed by flow-mediated dilation (FMD) of the brachial artery and TR jet velocity, respectively.

29 Immediate left brachial artery angiography with subsequent thrombectomy

30 croneurography), arterial blood pressure and brachial artery blood flow (duplex Doppler ultrasound) w

31 am), oxygen saturation (pulse oximetry), and brachial artery blood flow and shear rate (ultrasound) w

32 We assessed brachial artery blood flow during maximal handgrip exerc

33 he assessment of endothelial function in the brachial artery by flow-mediated dilatation (FMD).

34 s (IMT), flow-mediated vasodilatation of the brachial artery by ultrasound, assessment of endothelial

35 he assessment of endothelial function in the brachial artery by using flow-mediated dilation.

36 n alpha1 -adrenoceptor agonist) infusion via brachial artery catheter in response to two different st

37 alpha- and beta-adrenoceptor blockade (via a brachial artery catheter) to eliminate sympathoadrenal i

38 therapy were not apparent from conventional brachial artery cuff pressure assessments.

39 Before and after each exposure, brachial artery diameter (BAd) was assessed using ultras

40 Brachial artery diameter (BAD) was measured by ultrasoun

41 nd P = 0.005, respectively) alongside larger brachial artery diameter (P = 0.015) and lower FMD perce

42 fish consumption and a 0.10-mm lower (1 SD) brachial artery diameter in men (P = 0.01) and a 0.27% s

43 Brachial artery diameter, a predictor of cardiovascular

44 (p = 0.010) after controlling for changes in brachial artery diameter, reactive hyperemia, low-densit

45 esolution ultrasonography was used to assess brachial artery diameters at rest and following 5 minute

46 It was hypothesized brachial artery diameters of athletes would be larger, h

47 effect of a low-fat spread with added PSs on brachial artery endothelial function as measured by flow

48 Brachial artery endothelial function, pulmonary function

49 Cardiovascular profiles, brachial artery endothelial-dependent flow-mediated dila

50 Higher resting brachial artery flow (OR, 1.23 [95% CI, 1.04-1.46]) and

51 nd following 5 minutes of forearm occlusion (Brachial Artery Flow Mediated Dilation = BAFMD) and a co

52 ous and venous plasma carnitine difference x brachial artery flow), and carnitine disappearance (Rd)

53 Endothelial function assessed by brachial artery flow-mediated dilatation (FMD) was measu

54 systemic vasculature was investigated using brachial artery flow-mediated dilatation and carotid art

55 d endothelial function was assessed from the brachial artery flow-mediated dilatation response.

56 ve was to quantify endothelial function (via brachial artery flow-mediated dilatation) at sea level (

57 ve was to quantify endothelial function (via brachial artery flow-mediated dilatation) at sea level (

58 pressure, uterine artery pulsatility index, brachial artery flow-mediated dilatation, and serum conc

59 controlled pilot study, we observed improved brachial artery flow-mediated dilation (7.7 +/- 2.9% to

60 hed non-smoking control subjects we examined brachial artery flow-mediated dilation (FMD) and circula

61 ndpoint was the week 24 within-arm change in brachial artery flow-mediated dilation (FMD) in particip

62 Although brachial artery flow-mediated dilation (FMD) predicts re

63 was reconstructed by mathematical modeling; brachial artery flow-mediated dilation (FMD) was measure

64 take and brachial artery measures, including brachial artery flow-mediated dilation (FMD), has not be

65 Brachial artery flow-mediated dilation (FMD), urinary 8-

66 ammatory markers and vascular function using brachial artery flow-mediated dilation (FMD).

67 Coprimary end points included change in brachial artery flow-mediated dilation (FMDBA) and aorti

68 ly 50% (to 70 +/- 30 mmol/day), and conduit (brachial artery flow-mediated dilation [FMD(BA)]) and re

69 Endothelial function (brachial artery flow-mediated dilation [FMD]) was measur

70 mary end point was change in maximal percent brachial artery flow-mediated dilation after exposure.

71 ignificantly increased endothelium-dependent brachial artery flow-mediated dilation at 16 weeks, wher

72 outcome was change in endothelium-dependent brachial artery flow-mediated dilation at 16 weeks.

73 er high-density lipoprotein cholesterol, and brachial artery flow-mediated dilation compared with lea

74 Bruce protocol), applanation tonometry, and brachial artery flow-mediated dilation testing.

75 nded particles, the absolute maximal percent brachial artery flow-mediated dilation was reduced by 0.

76 ced endothelial dysfunction (as evaluated by brachial artery flow-mediated dilation) after 8 hours.

77 Brachial artery flow-mediated dilation, 24-hour urinary

78 Endothelial function was assessed as brachial artery flow-mediated dilation, and microvascula

79 Brachial artery flow-mediated dilation, digital pulse am

80 For brachial artery flow-mediated dilation, those in the tre

81 Secondary outcomes were brachial artery flow-mediated dilation, treadmill walkin

82 Vascular reactivity was measured by brachial artery flow-mediated dilation.

83 We measured vascular endothelial function by brachial artery flow-mediated dilation.

84 Primary endpoints were changes in brachial artery flow-mediated vasodilation (FMD), caroti

85 The primary outcome was the change in brachial artery flow-mediated vasodilation (FMD).

86 However, brachial artery FMD (ET: 3.8 +/- 3.0% vs. CT: 4.3 +/- 3.

87 Peak Vo2, brachial artery FMD in response to cuff ischemia, caroti

88 ntervention induced significant decreases in brachial artery FMD of all groups (P < 0.05).

89 METHODS AND Brachial artery FMD was measured in a nested case-cohort

90 tudies assessing carotid IMT and 7 assessing brachial artery FMD%.

91 Brachial artery FMD, carotid-femoral PWV, central AIx, a

92 ughout each exercise bout and in response to brachial artery FMD, measured prior to, immediately afte

93 s evaluated by flow-mediated dilation of the brachial artery in vivo and by vasomotor studies in saph

94 Flow-mediated dilatation of the brachial artery increased in the intervention group as c

95 (compared with <10%) significantly improved brachial artery macrovascular flow-mediated vasodilation

96 a similar directionality of association with brachial artery measures observed for nonfried fish cons

97 investigated cross-sectional associations of brachial artery measures with fish intake (ascertained w

98 The relation between dietary fish intake and brachial artery measures, including brachial artery flow

99 cant associations between fish intake or any brachial artery measures.

100 was measured by ultrasound before and after brachial artery occlusion [i.e., flow-mediated dilation

101 en consumption in the thenar eminence during brachial artery occlusion in sickle cell patients and he

102 essed by flow-mediated dilation (FMD) of the brachial artery preexposure, immediately postexposure, a

103 nd arterial stiffening was assessed from the brachial artery pulse pressure.

104 thickness (a measure of arterial stiffness), brachial artery reactivity (both flow-mediated dilatatio

105 ociated with carotid intima-media thickness, brachial artery reactivity-glycerol trinitrate, serum ur

106 greater retrograde shear likely modulate the brachial artery response, but the reduced total shear al

107 we conducted a novel assessment of vascular brachial artery responses both to ambient pollution and

108 Central haemodynamics, brachial artery shear rate (SR) and blood flow profiles

109 on between nonfried fish intake and baseline brachial artery size varies by sex, with suggestive evid

110 ned from the right internal jugular vein and brachial artery to determine concentration differences f

111 FMD and BAD were measured by brachial artery ultrasound at the initial examination of

112 and baseline arterial diameter (BAD) of the brachial artery using ultrasound in a large multicity co

113 After 30 minutes of rest, brachial artery vascular function was assessed by ultras

114 Flow-mediated dilation of the brachial artery was 25% smaller in ART than in control c

115 Following recovery, the brachial artery was cannulated and flushed with 10 000 U

116 ate, and flow-mediated dilation (FMD) of the brachial artery were evaluated in 123 study participants

117 ated endothelium-dependent relaxation of the brachial artery with doses of quercetin ranging from 50

118 lood pressure, flow-mediated dilation in the brachial artery, and carotid to radial pulse wave veloci

119 ction by flow-mediated dilation (FMD) of the brachial artery, and evaluated central arterial stiffnes

120 ges in flow-mediated dilatation (FMD) of the brachial artery, arterial stiffness, and blood pressure.

121 sured as flow-mediated dilation (FMD) of the brachial artery, has not been systematically assessed be

122 easured by flow-mediated vasodilation of the brachial artery, improved by 47% in the HiFI period comp

123 S AND RESULTS: Flow-mediated dilation of the brachial artery, matrix metalloproteinase-2 and matrix m

124 ssed systemic (flow-mediated dilation of the brachial artery, pulse-wave velocity, and carotid intima

125 improves flow-mediated dilation (FMD) of the brachial artery.

126 nd nitroglycerin-induced vasodilation of the brachial artery.

127 maging and cuff pressure measurements in the brachial artery.

128 ans of flow-mediated dilatation (FMD) of the brachial artery.

129 -induced flow-mediated dilation (FMD) of the brachial artery.

130 t, we assessed (1) flow-mediated dilation of brachial artery; (2) coronary flow reserve, ejection fra

131 toplethysmography and verified via automated brachial auscultation.

132 PAD was defined as an ankle-brachial blood pressure index of <0.9 in at least one le

133 Besides the known effect of RD on brachial blood pressure, the study showed for the first

134 smography (PVP) waveform and calibrate it to brachial BP levels estimated with population average met

135 ient-specific method was applied to estimate brachial BP levels from a cuff pressure waveform obtaine

136 a ensemble averaging and calibrate it to the brachial BP levels.

137 The study was to explore whether the brachial/carotid pulse pressure (B/C-PP) ratio selective

138 goal was to evaluate the effects of MetS on brachial central pulse pressure (PP), PP amplification,

139 d by venous occlusion plethysmography in the brachial circulation before and after intervention.

140 Brachial circumference (BC), also known as upper arm or

141 roximately 85%) before and after local intra-brachial combined blockade of NO synthase (NOS; via N(G)

142 These differences are not identifiable using brachial cuff pressures.

143 , 1.12; 95% CI, 0.99-1.27; P=0.06), baseline brachial diameter (HR, 1.09; 95% CI, 0.90-1.31; P=0.39),

144 However, obese children had greater brachial diameters and resting and hyperemic blood flow,

145 of an alternative ABI method and use of the brachial difference identifies individuals at an increas

146 e NgR ligands can promote regeneration after brachial dorsal root crush in adult rats.

147 tion of sensory axons to the brainstem after brachial dorsal root crush in adult rats.

148 Using measurements taken in the bilateral brachial, dorsalis pedis, and posterior tibial arteries,

149 Brachial endothelial function did not differ between sea

150 ignificantly associated with common carotid, brachial, femoral arterial parameters (lumen diameter [L

151 ean arterial pressure (P=0.04), and baseline brachial flow (P=0.002) were positively associated with

152 Other outcomes (brachial flow-mediated dilatation, microvascular reactiv

153 <25th percentile, absence of carotid plaque, brachial flow-mediated dilation >5% change, ankle-brachi

154 he highest increment (0.623 vs 0.784), while brachial flow-mediated dilation had the least (0.623 vs

155 ment with coronary artery calcium was 0.659, brachial flow-mediated dilation was 0.024, ankle-brachia

156 Carotid intima-media thickness and brachial flow-mediated dilation were not associated with

157 ntima-media thickness, ankle-brachial index, brachial flow-mediated dilation, high-sensitivity C-reac

158 edian CD4(+) count was 561 cells/microL, and brachial FMD was 4.2%.

159 ients) with critical limb ischemia and ankle brachial index >/=1.4 who underwent lower extremity angi

160 ial flow-mediated dilation >5% change, ankle-brachial index >0.9 and <1.3, high-sensitivity C-reactiv

161 sted after excluding participants with ankle brachial index >1.4 only as well as in subgroups defined

162 nary BPA levels (in tertiles) and PAD (ankle-brachial index < 0.9, n = 63) using logistic regression

163 nd severe prevalent PAD was defined as ankle brachial index </= 0.70, with both definitions also incl

164 achial index was used to diagnose PAD (ankle-brachial index </= 0.9).

165 Prevalent PAD was defined as ankle brachial index </= 0.90, and severe prevalent PAD was de

166 nts were enrolled based on an abnormal ankle-brachial index </=0.80 or a previous lower extremity rev

167 We defined PAD as an ankle-brachial index </=0.90.

168 Patients age 35 to 85 years with an ankle-brachial index </=0.95 and without clinically recognized

169 Toe brachial index <0.7 is more sensitive in diagnosing occl

170 g dampening was 43.6% sensitive, whereas toe brachial index <0.7 was 89.7% sensitive in diagnosing oc

171 Toe brachial index <0.7 was found in 75 of 83 (90.4%) limbs.

172 Incident PAD was determined by an ankle-brachial index <0.9 assessed at 2 subsequent examination

173 ipants were free of PAD, defined as an ankle brachial index <0.9 or >1.4 at baseline, and had complet

174 0 cases of incident PAD, defined as an ankle brachial index <0.9 or >1.4, were identified.

175 ntile for age, sex, and ethnicity; and ankle-brachial index <0.9.

176 PAD was defined as a baseline ankle-brachial index <0.9.

177 cipants were 384 men and women with an ankle brachial index <0.90 followed for a median of 47 months.

178 lative incidence of PAD, defined by an ankle brachial index <0.90 or a confirmed PAD event, with deat

179 arterial disease (PAD) was defined by ankle brachial index <0.90, coronary artery calcification (CAC

180 arteries (PCA) to those with a normal ankle-brachial index (ABI) and those with peripheral arterial

181 wed the evidence on the use of resting ankle-brachial index (ABI) as a screening test for PAD or as a

182 ve test for diagnosis of LE-PAD is the ankle-brachial index (ABI) at rest and typically an ABI </= 0.

183 etermine whether use of an alternative ankle-brachial index (ABI) calculation method improves mortali

184 A low ankle brachial index (ABI) indicates atherosclerosis and an in

185 efined peripheral artery disease as an ankle brachial index (ABI) lower than or equal to 0.90.

186 t to determine the association of high ankle brachial index (ABI) measurements with left ventricular

187 Patients were eligible if they had an ankle-brachial index (ABI) of 0.80 or less or had undergone pr

188 The ankle-brachial index (ABI) provides information on both athero

189 e association of both a low and a high ankle-brachial index (ABI) with incident cardiovascular events

190 y genetic variants associated with the ankle-brachial index (ABI), a noninvasive measure of PAD, we c

191 and changes in circulating PC levels, ankle brachial index (ABI), and walking impairment questionnai

192 of plaque, intima media thickness and ankle-brachial index (ABI), for N = 549.

193 ronary artery calcium (CAC) score, the ankle-brachial index (ABI), high-sensitivity C-reactive protei

194 ity were established by the use of the ankle-brachial index (ABI).

195 g different methods of calculating the ankle-brachial index (ABI).

196 e arsenic exposure and incident PAD by ankle brachial index (ABI).

197 without B-type natriuretic peptide and ankle-brachial index (C statistic, 0.79; 95% CI, 0.75-0.83 [re

198 ctors, B-type natriuretic peptide, and ankle-brachial index (model 6) yielded modest improvement over

199 ith carotid intima-media thickness and ankle-brachial index (two other measures of subclinical athero

200 PAD was defined based on an ankle.brachial index .0.90.

201 ng healthy subjects (YH) (n = 10; mean ankle-brachial index [ABI] 1.0 +/- 0.1, mean age 30 +/- 7 year

202 We assessed ankle-brachial index and hip bone mineral density, followed up

203 cipants with PAD, independently of the ankle-brachial index and other confounders.

204 The sensitivity of toe brachial index and pulse volume recording to predict tib

205 ertiary end points included changes in ankle-brachial index and quality-of-life assessments.

206 disease (PAD) identified by screening ankle-brachial index benefit from preventive therapies to redu

207 , 2.6 (95% CI, 1.4-4.8), and 39.2; for ankle-brachial index criteria, 0.6%, 9%, 5%, 2.3 (95% CI, 0.6-

208 mpared with patients enrolled based on ankle-brachial index criteria.

209 ed with patients enrolled based on the ankle-brachial index criterion.

210 ne cadmium, potential confounders, and ankle brachial index determinations in the follow-up examinati

211 f poorer cognitive performance were an ankle brachial index greater than 1.30 (OR, 18.56 [95% CI, 2.9

212 ect measures of arterial stiffness, an ankle brachial index greater than 1.30 and increased blood pre

213 Moreover, patients with lower ankle-brachial index had (1) a more delayed reactive hyperemia

214 C-reactive protein <2 mg/L and normal ankle-brachial index had DLRs >0.80.

215 than carotid intima-media thickness or ankle-brachial index in subjects without and with CKD (HR, 1.6

216 The ankle-brachial index in the Viabahn group significantly increa

217 Ankle brachial index measurement was performed at the baseline

218 Of these patients, 47.5% underwent ankle-brachial index measurement, 38.7% duplex ultrasound, 31.

219 ) had a history of claudication and an ankle-brachial index of <0.85 or prior revascularization for l

220 y had intermittent claudication and an ankle brachial index of <0.85, or if they had a prior peripher

221 74.4 (6.6) years, and had a mean (SD) ankle brachial index of 0.67 (0.18).

222 ascular obstruction of 50% or greater, ankle-brachial index of less than 0.90, or physician-diagnosed

223 %), or coronary artery disease with an ankle-brachial index of less than 0.90.

224 protein, family history of ASCVD, and ankle-brachial index recommendations by the American College o

225 ical limb ischemia and noncompressible ankle brachial index results, the prevalence of occlusive tibi

226 proximately 20% of patients undergoing ankle brachial index testing for critical limb ischemia have n

227 hial flow-mediated dilation was 0.024, ankle-brachial index was 0.036, carotid intima-media thickness

228 73% were male, and the median baseline ankle-brachial index was 0.78.

229 Ankle brachial index was measured, and participants reported t

230 The ankle-brachial index was used to diagnose PAD (ankle-brachial

231 Creatinine, age, and ankle-brachial index were among the top predictors of atrial f

232 al revascularization, smoking, and the ankle-brachial index were predictive of ALI.

233 ntimal medial thickness, stenosis, and ankle brachial index) and risk of dementia, CHD, and total mor

234 ction, microalbuminuria, and a reduced ankle-brachial index) in 2680 Framingham Study participants (m

235 Of 125 limbs with noncompressible ankle brachial index, 72 (57.6%) anterior tibial and 80 (64%)

236 ted for age, sex, race, comorbidities, ankle brachial index, and other confounders.

237 ain score, pain-free walking distance, ankle-brachial index, and transcutaneous oxygen measurements (

238 y outcomes quality of life, rest pain, ankle-brachial index, and transcutaneous oxygen pressure impro

239 rtality, adjusting for age, sex, race, ankle-brachial index, body mass index, smoking, comorbidities,

240 lcium, carotid intima-media thickness, ankle-brachial index, brachial flow-mediated dilation, high-se

241 ubclinical disease measures, including ankle-brachial index, carotid intimal-medial thickness, and ec

242 ody mass index, physical activity, the ankle brachial index, comorbidities, and other confounders.

243 operatively with physical examination, ankle brachial index, duplex, and a quality-of-life questionna

244 Coronary artery calcium, ankle-brachial index, high-sensitivity CRP, and family history

245 Coronary artery calcium, ankle-brachial index, high-sensitivity CRP, and family history

246 n of carotid intima-media thickness or ankle-brachial index, inclusion of the coronary artery calcium

247 Cell therapy significantly increased ankle brachial index, increased transcutaneous oxygen tension,

248 flexion inversely correlated with the ankle-brachial index, indicating that patients with more sever

249 p was found between floccular fossa size and brachial index, no significant relationship was found be

250 sodilation (assessed as the FMD%), the ankle-brachial index, or autopsy.

251 ifferences in claudication onset time, ankle-brachial index, or quality-of-life measurements between

252 Improvements in ankle-brachial index, Rutherford class, and quality of life we

253 but noninvasive measures, such as the ankle-brachial index, show that asymptomatic PAD is several ti

254 d for age, sex, race, body mass index, ankle-brachial index, smoking, physical activity, and comorbid

255 ts) precisely estimated the changes in ankle brachial index, transcutaneous oxygen tension, rest pain

256 tid artery intima-media thickness, and ankle-brachial index.

257 ted States were evaluated by screening ankle brachial indices <0.9 for peripheral artery disease (PAD

258 atrienoic acids and NO was assessed with the brachial infusion of inhibitors of cytochrome P450 epoxy

259 ibution and consensus sequences in axillary, brachial, inguinal, and mesenteric LNs were virtually id

260 scular conductance (FVC; Doppler ultrasound, brachial intra-arterial pressure via catheter) to local

261 roneal microneurography), arterial pressure (brachial line), CO (Modelflow), TPR and changes in forea

262 Increased T2 signal intensity and volume of brachial nerve roots do not exclude a diagnosis of ALS a

263 The association between brachial NO-dependent flow-mediated dilation (FMD) and c

264 oral and external iliac arteries but not the brachial or common carotid arteries and not correlated s

265 romatin domains, leading to specification of brachial or thoracic spinal identity.

266 ted in 10 patients who had been referred for brachial plexopathy at 3.0 T.

267 surgical replantation of avulsed roots after brachial plexus and cauda equina injuries.

268 rgeries to augment functional outcomes after brachial plexus and cauda equina injuries.

269 ized protocol of brachial plexus MR imaging, brachial plexus and limb-girdle muscle abnormalities wer

270 Axons traveling within the brachial plexus are responsible for the dexterous contro

271 es and can be used for MR neurography of the brachial plexus at 3.0 T.

272 or outpatient shoulder surgery, interscalene brachial plexus block (ISBPB) is currently the most pref

273 ocaine injected subcutaneously) or regional (brachial plexus block [BPB]) anaesthesia (0.5% L-bupivac

274 Anesthetic volumes in brachial plexus blockade may be reduced without compromi

275 praclavicular, infraclavicular, and axillary brachial plexus blocks, however, are all commonly used a

276 ations were urinary retention (4), transient brachial plexus injury, dislodgement of an intrauterine

277 as well as major nerves originating from the brachial plexus innervating the arm and hand) was perfor

278 By using an optimized protocol of brachial plexus MR imaging, brachial plexus and limb-gir

279 n in its role in the management of obstetric brachial plexus palsy, with investigation within 1 month

280 e magnetic resonance (MR) neurography of the brachial plexus with robust fat and blood suppression fo

281 manent functional deficit is avulsion of the brachial plexus.

282 of focal neuropathy primarily affecting the brachial plexus.

283 cted outcome more strongly than quartiles of brachial PP (p = 0.052).

284 fied covariates and quartiles of central and brachial PP.

285 wave reflection (augmentation index, carotid-brachial pressure amplification), and central pulse pres

286 patients on hemodialysis, we measured ankle-brachial pressure index (ABix) and evaluated mineral and

287 Ankle-brachial pressure index increased from 0.75 to 0.98 (P <

288 r older with a venous leg ulcer and an ankle brachial pressure index of at least 0.8, and were tolera

289 Beyond brachial pressure measurements, central hemodynamic para

290 Brachial pulse pressure (bPP), aoPP, and all measures of

291 measuring flow-mediated vasodilation (FMD), brachial pulse wave velocity (bPWV), circulating angioge

292 Central (carotid) to peripheral (brachial) pulse pressure amplification (PPA) was calcula

293 easured aortic pulse wave velocity (PWV) and brachial PWV to evaluate the stiffness gradient [(brachi

294 ial PWV to evaluate the stiffness gradient [(brachial PWV/aortic PWV)(0.5)] and ascending aortic and

295 On the head, they are confined to discrete brachial regions referred to as "arm pillars" that expan

296 Brachial stiffness, augmentation index, and systemic art

297 Brachial systolic and pulse pressure were also independe

298 The DASH/SRD reduced clinic and 24-hour brachial systolic pressure (155 +/- 35 to 138 +/- 30 and

299 reased difference between the left and right brachial systolic pressures.

300 decreased endothelial function according to brachial ultrasound results.